The partnership is part of AstraZeneca's Emerging Markets Health Innovation Hubs program. AstraZeneca will employ Qure.ai's solutions in the company's Emerging Markets region that spans Latin America, Asia, the Middle East, and Africa.

The collaboration will scale the use of Qure.ai's qXR tool, which automatically detects and localizes anomalies on chest radiographs, including those that could indicate lung cancer. The qXR tool has received the CE Mark and can detect lung cancer nodules from chest radiographs, according to the firm.

AstraZeneca's Emerging Markets Health Innovation Hubs will also work with Qure.ai to explore additional applications that leverage AI to identify and refer patients with radiographic lung abnormalities to specialists. Ultimately, the partnership aims to improve referral and diagnostic pathways for patients with possible lung cancers and to increase lung cancer detection at an earlier stage.

BioNTech, InstaDeep form AI lab
BioNTech and InstaDeep will form a joint artificial intelligence (AI) lab as part of a multiyear strategic collaboration.

AstraZeneca COVID-19 vaccine achieves 70% efficacy
AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating...

Iktos, Merck collaborate on AI for new drug designs
Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.

Samsung Biologics, AstraZeneca ink manufacturing deal
Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.

Cerevel, Cyclica partner on AI-based drug discovery
Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence (AI) to develop new neurological medicines.